Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice

Nat Rev Cardiol. 2010 Oct;7(10):549-50. doi: 10.1038/nrcardio.2010.126.

Authors

Sarina A van der Zee¹, Jonathan L Halperin

Affiliation

¹ The Zena and Michael A. Weiner Cardiovascular Institute and The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Box 1030, Mount Sinai Medical Center, 5th Avenue at 100th Street, New York, NY 10029, USA.

PMID: 20865027
DOI: 10.1038/nrcardio.2010.126

No abstract available

MeSH terms

Anticoagulants / adverse effects*
Anticoagulants / therapeutic use
Aryl Hydrocarbon Hydroxylases / genetics
Biomarkers, Pharmacological
Confidence Intervals
Cytochrome P-450 CYP2C9
Genetic Variation
Genotype
Hemorrhage / chemically induced*
Hemorrhage / genetics
Humans
International Normalized Ratio
Mixed Function Oxygenases / genetics
Vitamin K Epoxide Reductases
Warfarin / adverse effects*
Warfarin / therapeutic use

Substances

Anticoagulants
Biomarkers, Pharmacological
Warfarin
Mixed Function Oxygenases
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases
Vitamin K Epoxide Reductases